ADCs

Oncology

Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.

Oncology

At World ADC this month, the latest advances in ADC discovery and development were presented, debated, and reflected upon.

News

Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.

Oncology

News

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

Oncology

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?